Overview
Carrie-Anne Ridsdale (Carrie), who presents publicly as Jayne Price claimed Naloxone blocks drugs and alcohol for 20 minutes and authorised staff to override refusals, but these statements are medically incorrect and unsafe. Carrie also admitted administering Naloxone then delaying safeguarding referrals.
Early in 2024, Carrie publicly announced that their shops would carry Naloxone as a rescue medication for overdoses involving drugs and alcohol. They claimed staff were trained to administer it and asserted that Naloxone could block the effects of drugs, alcohol, and opioids for up to 20 minutes, presenting it as a life-saving intervention. Carrie also instructed staff to provide Naloxone immediately upon request, even if the person refused, and to administer it through clothing. They advised informing ambulance services after administration.
By early 2026, Carrie-Anne Ridsdale described real-world use of Naloxone, recounting an incident where a grandmother under the influence was given Naloxone and a referral was made to the police after the fact, rather than a real-time safeguarding intervention. Carrie also mentioned assisting vulnerable young people and making referrals due to safeguarding concerns. Despite claims of ceasing direct distribution, Carrie stated that Naloxone was still stocked in shops and that they had received training to distribute it.
A whistleblower report in mid-2026 raised concerns about medical-style procedures being conducted in non-clinical settings by Carrie, who claimed nursing experience. The same report described unsafe behaviour, including Carrie-Anne Ridsdale being under the influence of painkillers and morphine while responsible for premises.
Carrie's early claims about Naloxone's effects are factually incorrect: Naloxone does not block alcohol effects, and it is not authorised to override a patient's refusal. Carrie lacks verified clinical qualifications or NMC registration to train others in Naloxone administration. The delayed safeguarding referral after administering Naloxone is not consistent with statutory safeguarding duties. These issues raise significant safeguarding and clinical safety concerns.
Overall, Carrie's statements and conduct regarding Naloxone demonstrate a pattern of medically inaccurate information, unsafe practices, and inadequate safeguarding responses. The lack of clinical credentials and the admission of overriding refusals and delayed referrals indicate a serious risk to vulnerable individuals. These findings warrant regulatory and safeguarding attention.
